CHINA BULLETIN: Foreign Investor Flight
In this week’s issue foreign investor flight, a major mortgage rate cut and a former drug highflyer disbands. On a scale of 1 to 100, we give the week a…
With no cure in sight, drugs firm LianBio begins exit strategy
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
Structure Therapeutics Hopes to Wow Investors With Cutting-Edge Drug Tech
The maker of G-protein-coupled receptor (GPCR) drugs will raise more than $100 million in its IPO this week, making it the first major U.S. listing by a Chinese company this…
New Beijing Signals Reinforce China’s Intent to Reopen U.S. IPO Pipeline
The latest comments from top securities regulators follow the late December release of new regulations governing offshore listings by Chinese companies Key Takeaways: China Securities Regulatory Commission Chairman Yi Huiman…
Chinese Wheelchair Maker Tests U.S. Regulator’s Appetite for Controversial VIE Structure
Jin Medical is first Chinese firm using the variable interest entity (VIE) structure to apply for a New York IPO since the U.S. regulator temporarily banned such listings earlier this…
Medical Device Maker Highlights China Risk as Chinese U.S. IPOs Resume
Meihua International’s updated prospectus includes new section on Beijing’s intent to ‘exert more oversight and control’ over overseas Chinese listings Key Takeaways: Meihua International files updated prospectus highlighting China oversight…
FAST NEWS: LianBio Shares Sag in First U.S. IPO By a Chinese Company After Pause
The latest: Shares of biotech startup LianBio (LIAN.US) sagged in their trading debut on the Nasdaq, as the company became the first new listing by a Chinese firm in New…
Recent Articles
RELATED ARTICLES
-
CHINA BULLETIN: Manufacturing Contracts, Foreign Investment Plunges
- CHINA BULLETIN: China Further Extends Its Welcome Mat for Foreign Investors
- CHINA BULLETIN: China Eases Up on Cross-Border Data Requirements
- CHINA BULLETIN: Foreign Firms Put New Investments on Hold
- CHINA BULLETIN: China-U.S. Rapprochement Continues with Xi-Biden Call, Yellen Visit
- CHINA BULLETIN: Rare Signs of Improvement in Industrial Output, Retail Sales
- CHINA BULLETIN: More Trade Contraction
